Man Heals His Excruciating Pain With Cannabis After A Battery of Pharmaceuticals Failed
A man with excruciating pains following multiple traumas was monitored, daily, over one year while managing chronic pain by self-administering quantifiable amounts of natural
cannabis. Tetrahydro-cannabinol, Cannabidiol, and Cannabinol were all measured in tinctures, capsules, smoke-able product plus some baked goods, prior to their administration. By allowing
standardization, the man was able to develop a daily regimen of pain management that was
resistant to a battery of most patented analgesics.
More than 100 million people in the United States suffer from debilitating chronic pain. Pain resulting from a severe on-the-job injury
is a frustrating experience both for the patient as well as the
treating health practitioners and physicians. If pursuing conventional medical care, it leads to chronic dependence on
opiate painkillers and anti-depressants which eventually cause toxicity of the brain and metabolic function. However the relief
of pain may be less desired if quality of life of such
individuals is poor. The physician and the patients are left
with no option but to resort to alternative modes of
Cannabis has been documented to be one of such
measures, especially in advanced cases of cancer. It
holds an enormous potential as medicines derived from
cannabis plant exhibit a phenomenon termed strain
specific symptom relief. It has been documented to be of
proven value in arthritis and multiple sclerosis; however
few controlled clinical trials for its use in chronic intolerable
pain have been reported.
Some studies have examined the effect of adding a cannabinoid to the regimen of patients with chronic pain who report significant pain despite taking stable doses of potent opioids.
An investigational cannabinoid therapy helped provide effective analgesia when used as an adjuvant medication for cancer patients with pain that responded poorly to opioids, according to results of a multicenter trial reported in The Journal of Pain, published by the American Pain Society.
When patients begin to consume cannabis, there is a notable decline in the amount of prescribed medications taken, such as antipsychotics, mood stabilizers, and pain relievers. These drugs have severe side effects. There is not one clinical study which examined the use of cannabis for pain relief where subjects were not able to reduce their drug intake.
A U.S. Patent 6630507 was initiated in 2003 when researchers found that cannabinoids, high ratios which are found in marijuana, had specific antioxidant properties making them useful in the treatment and prophylaxis of wide variety of oxidation associated diseases, such as ischemic, age-related, inflammatory and autoimmune diseases. The cannabinoids are found to have particular application as neuroprotectants, for example in limiting neurological damage following ischemic insults, such as stroke and trauma, or in the treatment of neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease and HIV dementia. Nonpsychoactive cannabinoids, such as cannabidoil, are particularly advantageous to use because they avoid toxicity that is encountered with psychoactive cannabinoids at high doses useful in the method of the present invention.
involved in this study was a member of the Green Cross
Society of British Columbia, which has Federal tax number
to distribute cannabis for medical purposes. The Society provides natural product (cannabis, herbal medicine) to
its qualified members.
The volunteer, a 33 year old Caucasian male, volunteer was selected from the membership based on his record
keeping ability, the severity of his injury, plus his daily presence at the Society, allowing continuous monitoring.
The man kept detailed notes of his condition, including
pain charts, medications and dietary habits, allowing
comparison by study observers. The individuals note taking allowed an in depth review of his condition. The case described here is strikingly similar to four others of its type, run over the same year, with comparable observations and outcome.
The cannabis supplied by the Societys contracted growers was optimized for THC concentration through genetic selection of
specific strains, growing conditions and fertilizers.
Organic growing conditions were a priority.
For 15 months the man was monitored for all forms of
cannabis use. They accumulated data
on the amount of smoke-able, encapsulated, edible and
tincture preparations consumed by the man on a daily
basis. His prescription record, physicians notes, urine
(drug) tests, plus daily interviews were maintained and
examined. Daily cannabis use totaling 10 g of natural product cannabis, translating to an average of 420-500 mg of THC, 40-80 mg of CBD and 20-60 mg CBN, was
required to achieve a sufficient degree of pain management.
Significant reductions in daily pain scores as well as improved sleep, muscle spasm and general quality of life were achieved. The
patient was able to get back to the daily activities, do some part time volunteer work,
go to the gym, and lead what resembles a normal life.
consumed 10-15 g of cannabis per day. He also found
benefit in a number of supplements: for chronic pain and depression, including, GABA (500 mg), L- Tyrosine (500 mg), L-Tryptophan (550 mg), DL- Phenylalanine (500 mg) and S-adenosyl methionine (liquid) 40 drops a
day. For the breakthrough pain he used cannabis tincture
at 10 mg THC/drop; 2 mg CBD/drop: 15-25 drops (as
needed), which relieved intense pain, in a couple of
seconds. He also used Volcano (vaporizer), 2-4 g a day.
A medical examination showed all liver functions to be
normal, including clearance of the hypercholesterolemia.
There Is No Longer Doubt That Cannabis Addressed Pain Relief
The analgesic properties of cannabis are becoming well established in the literature. The purpose of this case study was to observe the efficacy and usefulness of the standardized whole plant cannabis
medicine. Indeed, the complexities of elucidating the
efficacy of such preparations is a difficult task, yet the
benefits of the natural product far outweigh the contrary in
consideration of toxicity, efficacy and side-effects. With
regard to the latter, more frequently unwanted side effects
from cannabis result from overdose than any other
parameter. And, most frequently, this overdose results
from oral ingestion of un-standardized baked goods (i.e.
Overdose results in confusion, paranoia and
fear that subsides after four to six hours, often into sleep.
In no case, has it been observed to cause permanent
physical or mental damage, but can often leave the
individual with extreme caution to repeating the event.
The second most frequently observed un-wanted side
effects arise from incorrect strain selection for the
For example, a person seeking pain relief and also suffering from anxiety, chooses a strain containing
high concentrations of CBN, with little comparative CBD
and low THC, may experience increased anxiety, with little
or no pain relief. Another important observation is that
there is a genealogical factor in tolerance experienced by
individuals of different ethnic backgrounds. Persons of
Celtic descent (Scottish, Irish or Welsh) appear to be 3 to 5
times more tolerant to cannabis than persons of middle
European or African descent. The person described in this
study had a Scottish mother, which may explain the high
THC levels required by him, but not by persons in similar
studies but of different ethnic background.
Proven Results With Cannabis
With 70% of the members
treating chronic pain the same phenomenon is observed
over and over that people achieve a significant degree of
pain management using standardized natural product
cannabis. Often a better quality of life is attained with cannabis use only. The subject in this study was nearly one year
using only natural product cannabis plus supplements for
his severe pain. He then went through yet another two
surgeries to back and hand using only cannabis for postoperative
Marco Torres is a research specialist, writer and consumer advocate for healthy lifestyles. He holds degrees in Public Health and Environmental Science and is a professional speaker on topics such as disease prevention, environmental toxins and health policy.